Verisfield bismuth quadruple tablet versus standard concomitant therapy for first-line Helicobacter pylori eradication

Phase 3, randomised, single-blind trial of metronidazole + bismuth oxide + tetracycline hydrochloride, metronidazole, amoxicillin, clarithromycin and esomeprazole in Helicobacter pylori infection (2 arms), sponsored by Verisfield. Primary endpoint: Successful clearance of Helicobacter pylori infection in the microbiological intention-to-treat population. Planned start Jul 2026; status: authorised.